Cystatin C is a marker for acute kidney injury, but not for mortality among COVID-19 patients in Mexico

BACKGROUND: Patients infected with SARS-CoV-2 can develop acute kidney injury (AKI), associated with adverse clinical outcomes. In Mexico, an AKI incidence of 60.7% was reported in patients with COVID-19. Serum cystatin C is a well-known marker for AKI. It has been postulated as a marker for mortali...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Santos, Karime, Cortes-Telles, Arturo, Uc-Miam, María Elena, Avila-Nava, Azalia, Lugo, Roberto, Aké, Rodolfo Chim, Gutiérrez-Solis, Ana Ligia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072838/
https://www.ncbi.nlm.nih.gov/pubmed/35576994
http://dx.doi.org/10.1016/j.bjid.2022.102365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072838/
https://www.ncbi.nlm.nih.gov/pubmed/35576994
http://dx.doi.org/10.1016/j.bjid.2022.102365

Ejemplares similares